Success of the capital increase by private placement for an amount of 15 million euros
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
Implementation of a new strategy and launch of a capital increase
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
18/04/2023 – AB Science today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12/04/2023 – AB Science today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a presentation on masitinib in amyotrophic lateral sclerosis (ALS) to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy…
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
04/04/2023 – AB Science today provides an update on the schedule for the evaluation by the European Medicines Agency (EMA) and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
AB Science webcast – Microtubule Destabilizer Agents (MDA) platform
16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast
AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
13/03/2023 – AB Science today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute myeloid leukemia (AML)
Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & Therapy
28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank
31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB)